# Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa

> **NCT05157958** · PHASE2 · UNKNOWN · sponsor: **Anterogen Co., Ltd.** · enrollment: 6 (estimated)

## Conditions studied

- Dystrophic Epidermolysis Bullosa

## Interventions

- **BIOLOGICAL:** ALLO-ASC-SHEET
- **OTHER:** Vehicle Control

## Key facts

- **NCT ID:** NCT05157958
- **Lead sponsor:** Anterogen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-01
- **Primary completion:** 2025-10-01
- **Final completion:** 2026-04-28
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2024-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05157958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05157958, "Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05157958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*